Search

HARMONY: Innovative Medicines Initiative approves € 40 million project for better care of patients with hematologic malignancies

HARMONY will capture, integrate, analyze and harmonize anonymous patient data from high-quality multidisciplinary sources to unlock valuable knowledge on multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), myelodysplastic syndromes (MDS)…

Read more

EHA’s advocacy for hematology continues

The EHA Board has recently approved five position papers which formulate EHA’s key lobbying priorities:

Support for hematology research in Horizon 2020 (and future EU research funding programs)
Access to treatment for patients with blood disorders
EU collaboration to reduce the prices…

Read more

Young researchers to benefit from EHA training and mentoring

Participation in EHA-CRTH will allow these researchers to fine-tune the skills and knowledge required to successfully design, run and complete clinical trials.

Read more

EHA-funded study in The Lancet Haematology: Economic Burden of Blood Disorders in EU is €23 billion

In Europe blood disorders affect around 80 million people. The total cost of blood disorders consists of healthcare expenditure (€15. 6 billion), productivity loss due to illness and mortality (€5. 6 billion), and the costs of informal care (€1.

Read more

European Reference Networks, a unique opportunity to take collaboration and patient care in hematology to the next level, was a core topic at EHA 2016

On Saturday 11 June, a session in the Patient Advocacy Track focused on the emerging European Reference Networks (ERNs).

Read more

Press Release: Economic burden of blood disorders in EU is €23 billion

The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more

Killer antibodies against AML

Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.

Read more

The Clot Thickens

Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).

Read more